Funding Opportunity RFA-FD-18-003 from the NIH Guide for Grants and Contracts. The Food and Drug Administration announces its intention to accept and consider a single source application for award to the World Health Organization (WHO) for the Building Research Capacity in Global Tobacco Product Regulation Program. The purpose of the Program is to identify, support, develop, conduct, and coordinate research efforts relating to tobacco control laws and rules in foreign countries that will directly inform and support FDAs exercise of its authority to regulate the manufacture, distribution, marketing and sale of tobacco products in the United States. The Program will advance FDA's Center for Tobacco Products' (CTPs) mission by utilizing the World Health Organizations (WHO) Member States expertise and extensive international contacts in global tobacco control, as well as WHO's own programmatic expertise, to inform and support adequate manufacture, distribution and market regulations of tobacco products for the protection of public health in the United States. The Program will also provide a universal public benefit by creating opportunities for collaboration and research development globally, thereby resulting in better-informed and effective tobacco product regulation around the world, and increased knowledge in the public sphere regarding tobacco use and its harms globally.

Funding Opportunity RFA-CA-17-044 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs), established under an earlier released RFA-CA-17-009 for U54 specialized centers. The DRSCs are designed to target the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Establish a network of multi-disciplinary research teams to study mechanisms of tumor resistance and sensitivity and develop innovative anti-cancer therapy strategies. The Coordinating Center to be established under this FOA will facilitate the activities of the DRSCs and help integrate the results of their studies.

Funding Opportunity RFA-CA-17-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches.

Funding Opportunity RFA-CA-17-039 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

Funding Opportunity PA-18-328 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support investigator-initiated R21 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations.

Funding Opportunity PA-18-316 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support investigator-initiated R01 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations.

Notice NOT-HS-18-001 from the NIH Guide for Grants and Contracts

Notice NOT-HS-18-002 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-405 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health disparities, and translation research that address the mission of the Institute. This FOA requires a minimum of three interrelated research projects that investigate a complex biomedical theme or research question. The projects may be supported by core units, if justified, to facilitate economy of effort, space, and equipment. The NHLBI provides support for Program Project Grants (PPGs) in the belief that collaborative research efforts can accelerate the acquisition of knowledge more effectively than a simple aggregate of research projects that have no interaction or thematic integration. NHLBI is particularly interested in encouraging new scientific directions in PPGs. Use of the P01 activity code is viewed as an opportunity to attract scientists who have not traditionally been supported by the NHLBI. Further, the PPG environment presents an opportunity for emerging scientific leaders to gain insight into how to lead a successful scientific Program, and applicants will have the opportunity to include a project led by an Early Stage Investigator (ESI). All projects in the Program must be interrelated and have objectives that address a central theme within the scientific mandate of the NHLBI.

Funding Opportunity RFA-GM-18-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide opportunities for eligible U.S. small business concerns (SBCs), in collaboration with academic partners, to conduct research to develop, implement, and test a comprehensive program for promoting biomedical entrepreneurship, technology (tech) transfer, management, small business finance, and other business skills needed to move basic discoveries and technologies out of the lab and into commercial products that improve patient care and enhance human health. This would be done by regional tech transfer accelerator hubs created by the awardee SBCs in partnership with academic institutions in Institutional Development Award (IDeA) states (https://www.nigms.nih.gov/Research/CRCB/IDeA/Pages/default.aspx). Each accelerator hub program will be expected to serve a network of several institutional sites across the IDeA states in one of the four regions where the academic partners are located. The goal of this FOA is to enhance the capacity to move scientific results from academic institutions into commercialization and promote a sustainable culture of biomedical entrepreneurship within IDeA states. The product of the funded research will be educational tools i.e., curricula, texts, webinars resulting from the development and testing of research accelerator models. It is anticipated that the educational tools developed under this FOA will be licensed or sold to other institutions that wish to create accelerator hubs.

Funding Opportunity RFA-CA-17-035 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic, multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

Funding Opportunity RFA-CA-17-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

Funding Opportunity RFA-CA-17-036 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

Funding Opportunity PAR-18-332 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for support of clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase l trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/therapeutics/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental drugs or biologics), or computational algorithms. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition. The U01 award may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use.

Funding Opportunity PAR-18-331 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.

Funding Opportunity RFA-CA-17-058 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications from institutions/organizations that propose to maintain a Canadian Collaborating Clinical Trials Network for the NCI National Clinical Trials Network (NCTN). The NCTN Canadian Collaborating Clinical Trials Network will be a full partner with the U.S. Network in the conduct of large-scale, multi-site clinical trials and help provide regulatory expertise/oversight for the conduct of NCTN trials in Canada. The competition for an award under this FOA is limited to eligible Canadian institutions.

Funding Opportunity RFA-CA-17-059 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications from institutions/organizations that propose to maintain or establish Network Lead Academic Participating Sites (LAPS) for the NCI National Clinical Trials Network (NCTN). The NCTN Network LAPS will provide scientific leadership by helping to develop and conduct clinical trials in association with one or more adult Network Groups and will contribute substantial accrual to clinical trials conducted across the entire NCTN.

Funding Opportunity RFA-CA-17-060 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications to maintain a Network Radiotherapy and Imaging Core Services Center for the NCI National Clinical Trials Network (NCTN) that provides scientific and technical expertise for incorporating integrated quality assurance and image data management for applicable NCTN clinical trials that involve interventions with radiotherapy and/or imaging modalities. In addition, the Center will have the capacity to provide similar services for other approved NCI-supported clinical trials network programs (e.g., the NCI/DCTD early phase clinical trial network program and the NCI/DCP NCI Community Oncology Research Program).

Funding Opportunity RFA-CA-17-061 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications from institutions/organizations that propose to maintain or establish Network Group Integrated Translational Science Centers for the NCI National Clinical Trials Network (NCTN). The NCTN Network Group Integrated Translational Science Centers will provide support for leadership and expertise to facilitate incorporating translational science into Network Group clinical trials, including the conduct of pilot projects to collect preliminary data.

Funding Opportunity PA-18-330 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to be conducted at no more than two clinical research centers. NIDDK is committed to improving the health of people with diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic and hematologic diseases. Applications for clinical trials submitted under this FOA should be hypothesis driven, have clearly described aims and objectives, and have a high likelihood that the trial findings will improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health.